Poorly Differentiated Neoplasms of Unknown Primary Site: Diagnostic Usefulness of a Molecular Cancer Classifier Assay

Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care

(2014) John D. Hainsworth et al.   VIRCHOWS ARCHIV

Blinded Comparator Study of Immunohistochemical Analysis versus a 92-Gene Cancer Classifier in the Diagnosis of the Primary Site in Metastatic Tumors

(2013) Lawrence M. Weiss et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Molecular Profiling Diagnosis in Unknown Primary Cancer: Accuracy and Ability to Complement Standard Pathology

(2013) F. Anthony Greco et al.   JNCI-Journal of the National Cancer Institute

A 92-gene cancer classifier predicts the site of origin for neuroendocrine tumors

(2013) Sarah E Kerr et al.   MODERN PATHOLOGY

Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells

(2012) T. Yamada et al.   CLINICAL CANCER RESEARCH

Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute

(2012) John D. Hainsworth et al.   JOURNAL OF CLINICAL ONCOLOGY

Performance and Clinical Evaluation of the 92-Gene Real-Time PCR Assay for Tumor Classification

(2011) Mark G. Erlander et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Pathologic Evaluation of Unknown Primary Cancer

(2009) Karin A. Oien   SEMINARS IN ONCOLOGY